Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate

British Journal of Pharmacology

Volumn 126, Issue 4, 1999, Pages 903-910

  Endo, Yasuo ^a   Shibazaki, Masahiko ^a   Yamaguchi, Kouji ^b   Nakamura, Masanori ^b   Kosugi, Hiroshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aminobisphosphonates; Bisphosphonates; Histamine; Histidine decarboxylase; Interleukin 1 (IL 1); Lipopolysaccharide (LPS)

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; HISTIDINE DECARBOXYLASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032935979     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702367     Document Type: Article

References (46)

1. ADAMI, S., BHALLA, A.K., DORIZZI, R., MONTESANI, F., ROSINI, S., SALVAGNO, G. & LO CASCIO, V. (1987). The acute phase response after bisphosphonate administration. Calcif. Tissue Int., 41, 326-331.
2. AURIOLA, S., FRITH, J.C., ROGERS, M.J., KOIVUNIEMI, A. & MÖNKKÖNEN, J. (1997). Identification of adenine nucleotidecontaining metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B., 704, 187-195.
3. BEER, J.D., MALTOFF, S.M. & ROCKLIN, R.E. (1983). The influence of histamine on immune and inflammatory responses. Adv. Imimmol., 35, 209-268
4. BONJOUR, J.P., RIZZOLI, R., AMMANN, p. & CHEVALLEY, T. (1994). Bisphosphonates in clinical medicine. In Bone and Mineral Research. Vol. 8. ed. Heershe, N.M. & Kanis, J.K. pp. 205-264. Amsterdam: Elsevier Science BV.
5. BYRON, J.W. (1977). Mechanism for histamine H2-receptor induced cell-cycle changes in the bone marrow stem cell. Agents'Actions, 7,209-213.
6. BYRON, J.W. (1980). Pharmacodynamic basis for the interaction of cimetidine with the bone marrow stem cells (CPUs). Exp. Hematol.. 8, 256-263.
7. DÜNN, C.J., DOYLE, D.V. & WILLOUGHBY, D.A. (1993b). Investigation of the acute and chronic anti-inflammatory properties of diphosphonates using a broad spectrum of immune and nonimmune inflammatory reactions. Drug Develop. Res., 28, 47-55.
8. DÜNN, C.J., GALINET, L.A., WU, H., NUGENT, R.A., SCHLACHTER, ST., STAITE, N.D., ASPAR, D.G., ELIOTT, G.A., ESSANI, N.A., ROHLOFF, N.A. & SMITH, R.J. (1993a). Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J. Pharmacol. Exp. Ther., 266, 1691-1698.
9. DY, M., MACHAVOINE, F., LEBEL, B., ICHIKAWA, A., GAST1NEL, L.N. & SCHNEIDER, E. (1993). Interleukin 3 promotes histamine synthesis in hematopietic progenitors by increasing histidine decarboxylase mRNA expression. Biochem. Biophys. Res. Commun., 192, 167-173.
10. ENDO, Y. (1982). Simultaneous induction of histidine and ornithine decarboxylases and changes in their product amines following the injection of Escherichia coli lipopolysaccharide into mice. Biochem. Pharmacol., 31, 1643- 1647.
11. ENDO, Y. (1983). Induction of histidine decarboxylase in mouse tissues by mitogens in vivo. Biochem. Pharmacol., 32,3835-3838.
12. ENDO, Y. (1989). Induction of histidine and ornithine decarboxylase activities in mouse tissues by recombinant interleukin-1 and tumor necrosis factor. Biochem. Pharmacol., 38, 1287-1292.
13. ENDO, Y. (1991). Parallel relationship between the increase in serotonin in the liver and the hypoglycaemia induced in mice by interleukin-1 and tumor necrosis factor. Imnnmol. Lett., 27, 7580.
14. ENDO, Y., KIKUCHI, T., NAKAMURA, M. & SHINODA, H. (1992a). Determination of histamine and polyamines in calcified tissues of mice: contribution of mast cells and histidine decarboxylase to the amount of histamine in the bone. Calcif. Tissue Int., 51, 67 71.
15. ENDO, Y., KIKUCHI, T., TAKEDA, Y., NITTA, Y., RIKIISHI, H & KUMAGAI, K. (1992b). GM-CSF and G-CSF stimulate the synthesis of histamine and putrescine in the hematopoietic organs in vivo, /mini/noJ. Lett., 33, 9-14.
16. ENDO, Y., NAKAMURA, N., KIKUCHI, T., SHINODA, H., TAKEDA, K., NITTA, Y. & KUMAGAI, K. (1993). Aminoalkylbisphosphonates, potent inhibitors of bone résorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes and osteoclasts in vivo. Calcif. Tissue Int., 52, 248-254.
17. ENDO, Y., NAKAMURA, M., NITTA, Y. & KUMAGAI, K. (1995). Effect of macrophage depletion on the induction of histidine decarboxylase by lipopolysaccharide interleukin-1 and tumor necrosis factor. Br. J. Pharmacol, 114, 187-193.
18. ENDO, Y., SUZUKI, R. & KUMAGAI, K. (1985). Interleukin-l-Iike factor can accumulate 5-hydroxytrytamine in the liver of mice and can induce hypoglycaemia. Biochem. Biophys. Ada, 840,37 42.
19. FALUS, A. & MERÉTEY, K. (1992). Histamine: an early messenger in inflammatory and immune reactions. Immunol. Today, 13, 154156.
20. FRITH, J.C., MÖNKKÖNEN, J., BLACKBURN, G.M., RÜSSEL, R.G. & ROGERS, M.J. (1997). Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res., 12, 1358-1367.
21. GEDDES, A.D., D'SOUZA, S.M., EBENTINO, F.H. & KENNETH, J.I. (1994). Bisphosphonates: structure-activity relationships and therapeutic implications. In Bone and Mineral Research. Vol. 8. ed. Heershe, N.M. & Kanis, J.K. pp. 265-306. Amsterdam: Elsevier Science BV.
22. GREEN, J.R., MÜLLER, G.K. & JAEGGI, K.A. (1994). Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Mineral Res., 9, 745-751.
23. GROSS, S. & WORTHINGTON-WHITE, D.A. (1984). Cimetidine suppression of CFU-C in male. Am. J. Hematol., 17, 279-286.
24. HUGHES, D.E., WRIGHT, K.R., UY, H.L., SASAKI, A., YONEDA, T., ROODMAN, G.D., MUNDY, G.R. & BOYCE, B.F. (1995). Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res., 10, 1478-1487.
25. LEBEL, B., SCHNEIDER, E., PIQUET-PELLORCE, C, MACHAVOINE, F., KINDER, V., LUFFAU, G. & DY, M. (1990). Antigenic challenge of immunized mice induces endogenous production of IL-3 that increases histamine synthesis in hematopoietic organs. J. Immunol., 145, 1222-1226.
26. LIN, J.H., CHEN, I.-W. & DUGGAN, D.E. (1992). Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab. Dispos., 20, 473-478.
27. MACAROL, V. & FRAUENFELDER, FT. (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am. J. Ophthamol, 118, 220-224.
28. MÖNKKÖNEN, J., KOPONEN, H.-M. & YLITALO, P. (1989). Comparison of the distribution of three bisphosphonates in mice. Pharmacol. Toxicol, 65, 294-298.
29. MÖNKKÖNEN, J., SIMILÄ, J. & ROGERS, M.J. (1998). Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Science, 62, PL 95-102.
30. MÜHLBAUER, R.C., BAUSS, F., SCHENK, R., JANNER, M., BUSIES, E., STREIN, K. & FLEISCH, H. (1991). BM 21.0955, a new bisphosphonate to inhibit bone résorption. J. Bone Afineral Res.,6, 1003-1011.
31. NAKAMURA, M., ANDO, T., MASATAKA, A., KUMAGAI, K. & ENDO, Y. (1996). Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br. J. Pharmacol., 119, 205-212.
32. NAKAYA, N. & TASAKA, K. (1988). The influence of histamine on precursors of granulocytic leukocytes in murine bone marrow. Life Sei., 42, 999-1010.
33. NUGENT, R.A., MURPHY, M., SCHLACHTER, S.T., DÜNN, C.J., SMITH, R.J., STAITE, N.D., GALINET, L.A., SHEILDS, S.K., ASPAR, D.G., RICHARD, K.A. & ROIILOFF, N.A. (1993). Pyrazoline bisphosphonate esters as novel anti-inflammatory and antiarthritic agents. J. Afed. Chem., 36, 134-139.
34. PENNANEN, N., LAPINJOKI, S., URTTI, A. & MÖNKKÖNEN, J. (1995). Effect of liposomal and free bisphosphonates on the IL\P, IL-6 and TNFa secretion from RAW264 cells in vitro. Pharmaceutical Res., 12, 916-922.
35. REITSMA, P.M., TEITELBAUM, S.L., BIJVOET, O.L.M. & KAHN, A.J. (1982). Differential action of the bisphosphonates (3-amino-lhydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (C12MDP) on rat macrophage-mediated bone résorption in vitro. J. Clin. Invest., 70, 927-933.
36. REY, A. & BESEDOVSKY, H. (1989). Antidiabetic effects of interleukin 1. Proc. Nail. Acad. Sei. U.S.A., 86, 5943-5947.
37. RODAN, G.A. & FLEISCH, H.A. (1996). Bisphosphonates: Mechanism of Action. J. Clin. Invest., 97, 2692-2696.
38. SAHNI, M., GUENTHER, H.L., FLEISCH, H., COLLIN, P. & MARTIN, T.J. (1993). Bisphosphonates act on rat bone résorption through the mediation of osteoblasts. J. Clin. Invest., 91, 2004-2011.
39. SALKOWSKI, C.A., NETA, R., WHYNN, T.A., STRASSMANN, G., VAN ROOIJEN, N. & VOGEL, S.N. (1995). Effect of liposome-mediated macrophage depletion on LPS-induced cytokine expression and radioprotection. J. InvnimoL. 155, 3168-3179.
40. SAUTY, A., PECHERSTORFER, M., ZIMMER-ROTH, I., FIORONI, P., JUILLERAT, L., MARKERT, M., LUDWIG, H., LEUENBERGER, P., BURCKHARDT, P. & THIÉBAUD, D. (1996). Interleukin-6 and tumor necrosis factor a leveles after bisphosponates treatment in vitro and in patients with malignancy. Bone, 18, 133-139.
41. SCHMIDT, A., RUTLEDGE, S.J., ENDO, N., OPAS, E.E., TANAKA, H., WESOLOWSKI, G., LEU, C.T., HUANG, Z. & RAMACHANDARAN, C. (1996). Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. Nail. Acad. Sei. U.S.A., 93, 3068-3073.
42. SCHNEIDER, E., PIQUET-PELLORCE, C. & DY, M. (1990). New role for histamine in interIeukin-3-induced proliferation of hematopoietic stem cells. J. Cell. Physiol., 143, 337-343.
43. SHOUNAN, Y. & YOU-HENG, X. (1988). The influence of histamine at various concentrations on the cell cycle state of hematopoietic stem cells (CFU-s). Int. J. Cell Cloning. 6, 290-295.
44. SIRIS, E. (1993). Bisphosphonateas and iritis. Lancet, ii, 436-437.
45. SUGAWARA, S., SHIBAZAKI, M., TAKADA, H., KOSUGI, K. & ENDO, Y. (1998). Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone résorption, on the lipopolysaccharideinduced production of interleukin-1 and tumour necrosis factor in mice. Br. J. Pharmacol., 125, 1735-1740.
46. VAN ROOIJEN, N. & SANDERS, A. (1994). Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Meth., 174, 83-93.